Search Results - "Griguolo, G."

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study by Guarneri, V., Dieci, M.V., Bisagni, G., Frassoldati, A., Bianchi, G.V., De Salvo, G.L., Orvieto, E., Urso, L., Pascual, T., Paré, L., Galván, P., Ambroggi, M., Giorgi, C.A., Moretti, G., Griguolo, G., Vicini, R., Prat, A., Conte, P.F.

“…In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower…”
Get full text

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival by Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M.V., Guarneri, V.

“…In the last years we have witnessed tremendous advancements in the treatment landscape of metastatic breast cancer (MBC), leading to a progressive prolongation…”
Get full text

A systematic review of contemporary phase I trials in patients with lymphoma by Griguolo, G., Zorzi, M.F., Pirosa, M.C., Treglia, G., Bertoni, F., Kuruvilla, J., Zucca, E., Stathis, A.

“…We performed a systematic review of phase I trials specifically designed for lymphoma patients. PubMed and Cochrane Library databases were searched using…”
Get full text

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials by Guarneri, V., Griguolo, G., Miglietta, F., Conte, P.F., Dieci, M.V., Girardi, F.

“…Studies testing the addition of lapatinib to neoadjuvant trastuzumab + chemotherapy reported an increase in pathologic complete response (pCR), with,…”
Get full text

Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials by Dieci, M. V., Frassoldati, A., Generali, D., Bisagni, G., Piacentini, F., Cavanna, L., Cagossi, K., Puglisi, F., Michelotti, A., Berardi, R., Banna, G., Goubar, A., Ficarra, G., Griguolo, G., Conte, Pierfranco, Guarneri, V.

“…Purpose The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic…”
Get full text

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer by Griguolo, G., Serna, G., Pascual, T., Fasani, R., Guardia, X., Chic, N., Paré, L., Pernas, S., Muñoz, M., Oliveira, M., Vidal, M., Llombart-Cussac, A., Cortés, J., Galván, P., Bermejo, B., Martínez, N., López, R., Morales, S., Garau, I., Manso, L., Alarcón, J., Martínez, E., Villagrasa, P., Prat, A., Nuciforo, P.

“…Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within…”
Get full text

Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? by Miglietta, F., Dieci, M.V., Griguolo, G., Guarneri, V., Conte, P.F.

“…•HER2-negative (HER2-) metastatic breast cancer (MBC) represents a biologically and clinically heterogeneous disease.•Chemotherapy is an important element of…”
Get full text

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab by Zulato, E, Bergamo, F, De Paoli, A, Griguolo, G, Esposito, G, De Salvo, G L, Mescoli, C, Rugge, M, Nardin, M, Di Grazia, L, Lonardi, S, Indraccolo, S, Zagonel, V

“…Background: AMP-activated protein kinase (AMPK) has a central role in cellular energy sensing and is activated in preclinical tumour models following…”
Get full text

Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors by Stathis, A., Hess, D., von Moos, R., Homicsko, K., Griguolo, G., Joerger, M., Mark, M., Ackermann, C. J., Allegrini, S., Catapano, C. V., Xyrafas, A., Enoiu, M., Berardi, S., Gargiulo, P., Sessa, C.

“…Summary Purpose To establish a recommended phase II dose (RP2D) for the oral smoothened inhibitor sonidegib in combination with paclitaxel; secondary…”
Get full text

ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC) by Griguolo, G., Brasó-Maristany, F., Pascual, T., Chic, N., Vidal, M., Adamo, B., Giarratano, T., Dieci, M.V., Guarneri, V., Prat, A.

Get full text

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409] by Miglietta, F., Bottosso, M., Griguolo, G., Dieci, M.V., Guarneri, V.

Get full text

Fat grafting for breast cancer patients: from basic science to clinical studies by Gennari, R, Griguolo, G, Dieci, M.V, Guarneri, V, Sibilio, A, Conte, P

“…Abstract Fat grafting in the surgical treatment of breast cancer has become popular in a short period of time because of the rising expectations of good…”
Get full text

Oncological outcome of fat grafting for breast reconstruction after cancer by Griguolo, G., Miglietta, F., Dieci, M.V., Vindigni, V., Bassetto, F., De Antoni, E., Polico, I., Marchet, A., Baldan, E., Vernaci, G., Saibene, T., Michieletto, S., Guarneri, V.

Get full text

A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure invasive lobular breast carcinoma (ILC) by Carbognin, L., Sperduti, I., Arpino, G., Dieci, M.V., Schettini, F., Griguolo, G., Brunelli, M., Guarneri, V., Nortilli, R., Fiorio, E., Pilotto, S., Orvieto, E., Manfrin, E., Conte, P., de Placido, S., Scambia, G., Tortora, G., Bria, E.

Get full text

Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study by Giarratano, T, Dieci, M V, Guarneri, V, Grosso, D, Zanocco, M, Faggioni, G, Falci, C, Ghiotto, C, Giorgi, C A, Griguolo, G, Mioranza, E, Pernice, G, Vernaci, G, Conte, P

Get full text

First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients by Dieci, M V, Guarneri, V, Giarratano, T, Mion, M, Tortora, G, Morandi, P, Gori, S, Merlini, L, Oliani, C, Pasini, F, Bonciarelli, G, Griguolo, G, Orvieto, E, Del Bianco, P, De Salvo, G L, Conte, P

Get full text

Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors by Forster, M, Sessa, C, Von Moos, R, Brown, N, Metaxas, Y, Griguolo, G, Lardelli, P, Iglesias, J, Fernandez-Teruel, C, Jandali, U, Soto-Matos, S.M, Stathis, A

Get full text

Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials by Dieci, M. V., Frassoldati, A., Generali, D., Bisagni, G., Piacentini, F., Cavanna, L., Cagossi, K., Puglisi, F., Michelotti, A., Berardi, R., Banna, G., Goubar, A., Ficarra, G., Griguolo, G., Conte, Pierfranco, Guarneri, V.

Get full text

A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC) by Carbognin, L, Sperduti, I, Arpino, G, Dieci, M V, Schettini, F, Guarneri, V, Griguolo, G, Nortilli, R, Fiorio, E, Parolin, V, Pilotto, S, Brunelli, M, Manfrin, E, Orvieto, E, Pellini, F, Pollini, G P, Conte, P, De Placido, S, Tortora, G, Bria, E

Get full text

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study by Schettini, F., Conte, B., Buono, G., De Placido, P., Parola, S., Griguolo, G., Fabi, A., Bighin, C., Riccardi, F., Cianniello, D., De Laurentiis, M., Puglisi, F., Pelizzari, G., Bonotto, M., Russo, S., Frassoldati, A., Pazzola, A., Montemurro, F., Lambertini, M., Guarneri, V., Cognetti, F., Locci, M., Generali, D., Conte, P., De Placido, S., Giuliano, M., Arpino, G., Del Mastro, L.

“…The current standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive (+) metastatic breast cancer is the combination of…”
Get full text